| Ytd | -71.67% | |
| 1y | -29.35% |
| Open | 2.96 | Prev Close | 2.10 | Low | 2.13 | High | 3.14 | Mkt Cap | 18.80M |
| Vol | 98.11M | Avg Vol | 35.08K | EPS | -1.85 | P/E | N/A | Forward P/E | -3.87 |
| Beta | 0.40 | Short Ratio | 2.80 | Inst. Own | 9.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 2.16 | 200-d Avg | 4.39 | 1yr Est | 21.50 |
LPCN News
Canada approves Lipocine’s TLANDO for adult males with testosterone deficiency. Partner Verity Pharm
U.S. stocks fell Wednesday; Dow dropped 350 points. Energy rose, materials slid. Constellation beat
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 59.2% to $1.99 during Wednesday&
SALT LAKE CITY, Oct. 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutica
Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company focused on the development of novel
Lipocine (LPCN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the co
HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Neutral and anno
Study informed by encouraging exploratory efficacy findings and a favorable safety profile in the pr
SALT LAKE CITY, Sept. 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceuti
SALT LAKE CITY, Aug. 4, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutica
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.32) per share which beat the analyst consens
SALT LAKE CITY, Aug. 3, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical compa
Live webinar to take place on Friday, June 12, 2026 at 11:00 AM Eastern Time SALT LAKE CITY, June 4,
Oral Presentation detailsTitle:Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpart
SALT LAKE CITY, May 19, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical compa
BASEL, Switzerland, May 19, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pio
SALT LAKE CITY, May 18, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical compa
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.54) per share which missed the analyst conse
Lipocine (LPCN) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimat
SALT LAKE CITY, May 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical compan
Mangoceuticals (NASDAQ: MGRX - Get Free Report) and Lipocine (NASDAQ: LPCN - Get Free Report) are bo
Lipocine Inc. (NASDAQ: LPCN - Get Free Report) Director John Higuchi acquired 40,000 shares of the c
Lipocine Inc. (NASDAQ: LPCN - Get Free Report) CEO Mahesh Patel bought 25,000 shares of the company'
BofA downgrades Carvana (CVNA) to Neutral, cutting the price target to $360. Explore the latest anal
On Thursday, the company said LPCN 1154 did not meet its primary endpoint in a Phase 3 trial for pos
Lipocine stock rebounds after a steep drop as LPCN 1154 misses the Phase 3 endpoint, with encouragin
Wall Street analysts changed their outlook on top names. Check out the ratings page for complete cha
SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims
US stocks fall, Dow drops over 50 points, real estate shares rise, Acuity Inc. shares decline, Sky Q
Lipocine said LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D17
Lipocine Inc. shares are trading lower Thursday after reporting topline safety and efficacy results
US stocks traded lower on Thursday, with the Nasdaq falling 1%. Energy shares rose, while consumer d
In the Phase 3 study population (N=90) of patients with PPD, LPCN 1154 did not show a statistically
In the Phase 3 study population (N=90) of patients with PPD, LPCN 1154 did not show a statistically
SALT LAKE CITY, March 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical com
HC Wainwright & Co. analyst Yi Chen maintains Lipocine (NASDAQ:LPCN) with a Buy and raises th
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology plat
Company on track to report topline results early in the second quarter of 2026Second planned Data an
https://ppubs.uspto.gov/api/pdf/downloadPdf/12502396?requestToken=eyJzdWIiOiJiNGI3ZTk4MS0wOTJiLTQyZj
Second Drug Safety Monitoring Board (DSMB) meeting update planned for mid-January 2026Topline result
Per the Drug Safety Monitoring Board (DSMB) meeting evaluating one-third of planned participants, st
HC Wainwright & Co. analyst Yi Chen maintains Lipocine (NASDAQ:LPCN) with a Buy and lowers th
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.59) per share which missed the analyst conse
HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintain
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.41) per share which missed the analyst conse
HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintain
HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintain
New Drug Submission filed by Lipocine's licensing partner Verity PharmaOver 700,000 total prescr